Sunday, June 08, 2025 3:07:51 PM
Thanks Ex,
I'm no judge of whether any of these systems can do the job for us as well as the EDEN, you've made your point that other systems do exist.
I'm sure that LP has determined that we're best served by owning the system we're using, rather than paying someone else to use theirs, but that decision may have resulted in mass production delays, but no doubt will keep our cost lower.
Until we have more information about our EDEN system, I don't think it's possible to say if we have advantages, or not, over other such systems for production of certain personal products. From the manuscript you cited, it sounded like many companies are still making their approved products manually, or at least partially manually. I don't know how many of these systems have been tried and found to meet manufacturing needs in approved therapeutics.
Am I right in expecting that any product developed and approved with manual production must undergo the same sort of comparison trials when manufacturing is changed to one of these systems, even if the system has been approved for other products.
I think that if the EDEN is built to be monitored remotely for its operation, so NWBO can track every dose of vaccine produced, it may offer something the others may not. Clearly, I'm not certain of that. I just don't know if you purchased the device from someone else if you could monitor it's use, or if it would be done by whoever you purchase from, or perhaps not at all.
Gary
I'm no judge of whether any of these systems can do the job for us as well as the EDEN, you've made your point that other systems do exist.
I'm sure that LP has determined that we're best served by owning the system we're using, rather than paying someone else to use theirs, but that decision may have resulted in mass production delays, but no doubt will keep our cost lower.
Until we have more information about our EDEN system, I don't think it's possible to say if we have advantages, or not, over other such systems for production of certain personal products. From the manuscript you cited, it sounded like many companies are still making their approved products manually, or at least partially manually. I don't know how many of these systems have been tried and found to meet manufacturing needs in approved therapeutics.
Am I right in expecting that any product developed and approved with manual production must undergo the same sort of comparison trials when manufacturing is changed to one of these systems, even if the system has been approved for other products.
I think that if the EDEN is built to be monitored remotely for its operation, so NWBO can track every dose of vaccine produced, it may offer something the others may not. Clearly, I'm not certain of that. I just don't know if you purchased the device from someone else if you could monitor it's use, or if it would be done by whoever you purchase from, or perhaps not at all.
Gary
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
